A Service For Professionals Saturday, December 16, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Saturday, December 16, 2017 11610 Sources 421,645,633 Articles 2,875,095 Readers
Contact (202) 540-8337

Rheumatoid Arthritis: Beyond TNF Inhibitors, 2026

/EIN News/ -- Dublin, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026" report to their offering.

The Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016-2026 report provides a comprehensive analysis of the current market landscape of rheumatoid arthritis based therapies (specifically, non - tumor necrosis factor (TNF) inhibitors) and an informed opinion on how the market is likely to evolve over the next decade. RA is known to substantially affect patients' quality of life and is characterized by a more severe set of symptoms than those observed in patients with osteoarthritis.

The RA market is primarily populated by DMARDs that have been shown to alter the course of the disease and also improve radiographic outcomes. Biologic DMARDs including TNF inhibitors, such as HUMIRA® (USD 14 billion) , Enbrel® (USD 9 billion) , and REMICADE® (USD 6.6 billion) , are counted among the best-selling drugs in this market. In recent years, treatment options for RA have increased substantially with the development of several novel drugs/drug classes. In addition to TNF inhibitors, a number of novel biologic DMARDs, such as T-cell costimulatory blocking agents (Orencia®), B-cell depleting agents (Rituxan®), interleukin-6 (IL-6) inhibitors (Actemra®) and interleukin-1 (IL-1) receptor antagonists (Kineret®), have been approved over the past few years.

In 2012, Xeljanz®, the first oral non-biologic DMARD belonging to the janus kinase (JAK) inhibitors drug class was approved in the US. The drug generated revenues worth USD 523 million in 2015 alone. In comparison to traditional biologic DMARDs, which are delivered through injections or infusions, JAK inhibitors, or Jakinibs, are a new class of drugs that have been optimized for oral delivery.

It is also worth mentioning that a number of pharmaceutical companies are developing drugs with novel mechanisms of action, namely Bruton's tyrosine kinase (BTK) inhibitors, spleen tyrosine kinase (SYK) inhibitors, RANKL inhibitors and adenosine A3 receptor (A3AR) agonists, which (along with Jakinibs) represent the next generation of drugs designed to treat RA.

During the course of our study, we identified over 80 non-TNF inhibitors that are either already marketed or in various phases of development for the treatment of RA; of these, five drugs are currently marketed and four drugs (a JAK inhibitor, a RANKL inhibitor and two IL-6R inhibitors) are in the pre-registration stage. Overall, more than 60% of candidate drugs are currently under clinical development. Drug development efforts in this domain are being actively led by a mix of pharmaceutical giants, mid-sized companies and start-ups.

Among other things, the report features discussions on:

- The current state of the market with respect to available drug classes, key players, phase of development of pipeline products (clinical and preclinical/discovery), route of administration, type of molecule and type of therapy.
- An in-depth analysis comprising of schematic representations, including a grid analysis highlighting the distribution of pipeline, an overview of the landscape of industrial developers (small, mid-sized and large players) and the geographical distribution of the companies involved in the development of RA therapeutics.
- Detailed profiles of drugs that have been recently (post-2010) approved/marketed or are in the late stages of development (phase III and above).
- Information on the mechanisms of action of novel drugs (non-TNF inhibitor) that are currently being investigated as potential treatment options for RA.
- Detailed comparative analysis of the key clinical trial endpoints for drugs that are already marketed or are in phase III of development and insights on the clinical development programs designed for phase III drugs (active comparator trials, important primary endpoints and scale of trials).
- A detailed analysis of the collaborations and agreements established amongst stakeholders in the past few years.
- Emerging trends and a discussion on the popularity of non-TNF inhibitors on Twitter over the last few years.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Novel Drugs to Treat Rheumatoid Arthritis: Key Mechanisms of Action

6. JAK Inhibitors

7. Interleukin-6 Inhibitors

8. Novel Drugs for Rheumatoid Arthritis

9. Market Forecast

10. Key Insights

11. Recent Collaborations

12. Emerging Trends on Social Media

13. Conclusion

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

- AB Science
- AbbVie
- Abbott Laboratories
- Acetylon Pharmaceuticals
- Aclaris Therapeutics
- Adverum Biotechnologies
- Aegera Therapeutics
- Alder BioPharmaceuticals
- Allergan
- Almac Group
- Amgen
- Antitope
- ArGentis Pharmaceuticals
- Arrien Pharmaceuticals
- Arthrogen
- Asahi Kasei Pharma Corporation
- Asana BioSciences
- Astellas Pharma
- AstraZeneca
- Atlantic Bio Sci
- Avexxin
- Bayer HealthCare
- BeiGene
- Biogen Idec
- Bird Rock Bio
- Boehringer Ingelheim
- Bristol-Myers Squibb
- CASI Pharmaceuticals
- CJ HealthCare
- CMC Biologics
- CONBA Pharmaceuticals
- Can-Fite BioPharma
- Centocor
- ChemoCentryx
- Chugai Pharmaceuticals
- Cipher Pharmaceuticals
- CleveXel Pharma
- Commence Bio
- Cyclacel
- Daiichi Sankyo
- Dendright Technology
- Dynamix Pharmaceuticals
- Eli Lilly
- Eternity Bioscience
- Evotec
- Five Prime Therapeutics
- Galapagos
- Genentech
- Genor BioPharma
- Genosco
- Gilead Sciences
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Hanmi Pharmaceutical
- HitGen
- Hubei Bio Pharmaceutical Industry Technology Institute
- Human Genome Sciences
- Hutchison Medi Pharma
- Iltoo Pharma
- Immune Response Biopharma
- Immunex
- ImmusanT
- Incyte Corporation
- Innate Pharma
- Intarcia Therapeutics
- Janssen
- Jiangsu Hengrui Medicine
- KBP BioSciences
- Kangstem Biotech
- Kwangdong Pharmaceutical
- Levolta Pharmaceuticals
- Lexicon Pharmaceuticals
- MacroGenics
- MedImmune
- Merck Serono
- Mesoblast
- Molecular Partners
- MorphoSys
- Morphotek
- NapaJen Pharma
- NovImmune
- Novartis
- Numab
- Ono Pharmaceutical
- Ortho Biotech
- Oscotec
- Peptinov
- Pfizer
- Philogen
- Pivotal BioSciences
- Portola Pharmaceuticals
- Principia Biopharma
- Protalex
- RedHill Biopharma
- Redx Pharma
- Regeneron Pharmaceuticals
- Rigel Pharmaceuticals
- Roche
- Rottapharm Biotech
- SBI Biotech
- Sanofi-Aventis
- Seikagaku Corporation
- Sevion Therapeutics
- Shanghai Institute of Materia Medica
- Sorrento Therapeutics
- Sun Pharma
- Sunesis Pharmaceuticals
- Taiho Pharmaceutical
- Takeda Pharmaceuticals
- TechnoPhage
- The Veterans Affairs Medical Center of Memphis
- TiGenix
- Toleranzia
- Translational Biosciences
- University of Melbourne
- University of Tennessee Health Science Center
- Vitae Pharmaceuticals
- Vitaeris
- WuXi AppTec
- Xencor
- Yungjin Pharmaceutical
- Ziarco Pharma

For more information about this report visit http://www.researchandmarkets.com/research/kcdqt3/rheumatoid

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Immune Disorders Drugs

Primary Logo

Powered by EIN News